David Mengel1, Wei Hong1, Grant T Corbett1, Wen Liu1, Alexandra DeSousa1, Laura Solforosi2, Cheng Fang3, Matthew P Frosch4, John Collinge5, David A Harris3, Dominic M Walsh6. 1. Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 2. Laboratory of Microbiology and Virology, University Vita-Salute San Raffaele, Milan, Italy. 3. Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA. 4. Massachusetts General Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA. 5. Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; MRC Prion Unit at UCL, UCL Institute of Prion Diseases and NHS National Prion Clinic, UCL Hospitals NHS Foundation Trust, London, United Kingdom. 6. Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: dwalsh3@bwh.harvard.edu.
Abstract
BACKGROUND: The prion protein (PrP) is known to bind certain soluble aggregates of the amyloid β-protein (Aβ), and two regions of PrP, one centered around residues 19-33, and the other around 87-112, are thought to be particularly important for this interaction. When either of these sequences are grafted into a human IgG the resulting antibodies react with disease-associated PrP conformers, whereas the parental b12 IgG does not. METHODS: Human antibodies containing grafts of PrP 19-33 or 87-112 were prepared as before (Solforosi et al., 2007) and tested for their ability to recognize synthetic and Alzheimer's disease (AD) brain-derived Aβ. Since aqueous extracts of AD brain contain a complex mixture of active and inactive Aβ species, we also assessed whether PrP-grafted antibodies could protect against neuritotoxicity mediated by AD brain-derived Aβ. For these experiments, human iPSC-derived neurons were grown in 96-well plates at 5000 cells per well and on post-induction day 21, AD brain extracts were added +/- test antibodies. Neurons were imaged for 3 days using an IncuCyte live-cell imaging system, and neurite number and density quantified. RESULTS: Grafted antibodies bound a significant portion of aggregated Aβ in aqueous AD extracts, but when these antibodies were co-incubated with neurons treated with brain extracts they did not reduce toxicity. By contrast, the PrP fragment N1 did protect against Aβ. CONCLUSIONS: These results further demonstrate that not all Aβ oligomers are toxic and suggest that PrP derivatives may allow development of agents that differentially recognize toxic and innocuous Aβ aggregates.
BACKGROUND: The prion protein (PrP) is known to bind certain soluble aggregates of the amyloid β-protein (Aβ), and two regions of PrP, one centered around residues 19-33, and the other around 87-112, are thought to be particularly important for this interaction. When either of these sequences are grafted into a human IgG the resulting antibodies react with disease-associated PrP conformers, whereas the parental b12 IgG does not. METHODS:Human antibodies containing grafts of PrP 19-33 or 87-112 were prepared as before (Solforosi et al., 2007) and tested for their ability to recognize synthetic and Alzheimer's disease (AD) brain-derived Aβ. Since aqueous extracts of AD brain contain a complex mixture of active and inactive Aβ species, we also assessed whether PrP-grafted antibodies could protect against neuritotoxicity mediated by AD brain-derived Aβ. For these experiments, human iPSC-derived neurons were grown in 96-well plates at 5000 cells per well and on post-induction day 21, AD brain extracts were added +/- test antibodies. Neurons were imaged for 3 days using an IncuCyte live-cell imaging system, and neurite number and density quantified. RESULTS: Grafted antibodies bound a significant portion of aggregated Aβ in aqueous AD extracts, but when these antibodies were co-incubated with neurons treated with brain extracts they did not reduce toxicity. By contrast, the PrP fragment N1 did protect against Aβ. CONCLUSIONS: These results further demonstrate that not all Aβ oligomers are toxic and suggest that PrP derivatives may allow development of agents that differentially recognize toxic and innocuous Aβ aggregates.
Authors: Jessica M Mc Donald; Tiernan T O'Malley; Wen Liu; Alexandra J Mably; Gunnar Brinkmalm; Erik Portelius; William M Wittbold; Matthew P Frosch; Dominic M Walsh Journal: Alzheimers Dement Date: 2015-04-04 Impact factor: 21.566
Authors: Tiernan T O'Malley; Nur Alia Oktaviani; Dainan Zhang; Aleksey Lomakin; Brian O'Nuallain; Sara Linse; George B Benedek; Michael J Rowan; Frans A A Mulder; Dominic M Walsh Journal: Biochem J Date: 2014-08-01 Impact factor: 3.857
Authors: Andrew D Watt; Keyla A Perez; Alan Rembach; Nicki A Sherrat; Lin Wai Hung; Timothy Johanssen; Catriona A McLean; Woan Mei Kok; Craig A Hutton; Michelle Fodero-Tavoletti; Colin L Masters; Victor L Villemagne; Kevin J Barnham Journal: Acta Neuropathol Date: 2013-01-25 Impact factor: 17.088
Authors: Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux Journal: Chem Rev Date: 2021-02-05 Impact factor: 60.622
Authors: Grant T Corbett; Zemin Wang; Wei Hong; Marti Colom-Cadena; Jamie Rose; Meichen Liao; Adhana Asfaw; Tia C Hall; Lai Ding; Alexandra DeSousa; Matthew P Frosch; John Collinge; David A Harris; Michael S Perkinton; Tara L Spires-Jones; Tracy L Young-Pearse; Andrew Billinton; Dominic M Walsh Journal: Acta Neuropathol Date: 2019-12-18 Impact factor: 17.088
Authors: Carlo Scialò; Luigi Celauro; Marco Zattoni; Thanh Hoa Tran; Edoardo Bistaffa; Fabio Moda; Robert Kammerer; Emanuele Buratti; Giuseppe Legname Journal: Viruses Date: 2021-08-17 Impact factor: 5.048
Authors: Inês Mollet; João Pedro Marto; Marcelo Mendonça; Miguel Viana Baptista; Helena L A Vieira Journal: Mol Neurobiol Date: 2021-10-22 Impact factor: 5.682